8
Registered trials
4
Recruiting
6
Unique sponsors
5
Unique IMPs
6
Commercial trials
Drug classes (ATC)
—
ATC code not specified
8
Mechanism of action (INN-stem analysis)
Unknown / small molecule
5 substances
Phase III:
1
Phase II:
3
Phase I/II:
1
Phase I:
2
Phase I (Other):
1
Phase III
1 trial-
RecruitingUniversitaet Muenster AcademicTTF-NGR
Phase II
3 trials-
EndedUSWM Ct LLC CommercialAFAMITRESGENE AUTOLEUCEL
-
EndedUSWM Ct LLC CommercialLETETRESGENE AUTOLEUCEL
-
RecruitingUniversitaetsklinikum Tuebingen AöR AcademicPERVI-FUS, PERVI-NEO, 11902A
Phase I/II
1 trial-
EndedEpizyme Inc. CommercialTAZEMETOSTAT
Phase I
2 trials-
RecruitingImmunocore Limited CommercialIMP not specified
-
PendingMedigene AG CommercialIMP not specified
Phase I (Other)
1 trial-
RecruitingUSWM Ct LLC CommercialLETETRESGENE AUTOLEUCEL
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| USWM Ct LLC | Commercial | 3 | Phase I (Other), Phase II | 1 |
| Immunocore Limited | Commercial | 1 | Phase I | 1 |
| Medigene AG | Commercial | 1 | Phase I | 0 |
| Epizyme Inc. | Commercial | 1 | Phase I/II | 0 |
| Universitaetsklinikum Tuebingen AöR | Academic | 1 | Phase II | 1 |
| Universitaet Muenster | Academic | 1 | Phase III | 1 |
New trials by year
2019
1
2020
2
2021
1
2023
1
2024
1